Advanced search
1 file | 2.07 MB

A longitudinal analysis of IDO and PDL1 expression during immune- or targeted therapy in advanced melanoma

(2018) NEOPLASIA. 20(2). p.218-225
Author
Organization
Abstract
A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma patients treated with IT and targeted therapy (TT). Intraindividual biopsies taken after a period of weeks to months demonstrate discordant results in 30% of the cases. Overlap of IDO and PDL1 increased after therapy. IT only marginally impacted PDL1 expression over time in contrast to TT. Standardized repeated assessments of multiple immune markers in repeated biopsies will generate detailed insights in melanoma's immune evolution and adaption during therapies and might be used to support treatment decisions.
Keywords
CLINICAL-PRACTICE GUIDELINES, INDOLEAMINE 2, 3-DIOXYGENASE, UNTREATED MELANOMA, CANCER, NIVOLUMAB, IPILIMUMAB, DIAGNOSIS, ANTIBODY, MARKER, PD-L1

Downloads

  • LB 1-s2.0-S1476558617304992-main.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.07 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Krähenbühl, Lukas, Simone M Goldinger, Joanna Mangana, Katrin Kerl, Ines Chevolet, Lieve Brochez, Christine Horak, Mitch Levesque, Reinhard Dummer, and Phil F Cheng. 2018. “A Longitudinal Analysis of IDO and PDL1 Expression During Immune- or Targeted Therapy in Advanced Melanoma.” Neoplasia 20 (2): 218–225.
APA
Krähenbühl, L., Goldinger, S. M., Mangana, J., Kerl, K., Chevolet, I., Brochez, L., Horak, C., et al. (2018). A longitudinal analysis of IDO and PDL1 expression during immune- or targeted therapy in advanced melanoma. NEOPLASIA, 20(2), 218–225.
Vancouver
1.
Krähenbühl L, Goldinger SM, Mangana J, Kerl K, Chevolet I, Brochez L, et al. A longitudinal analysis of IDO and PDL1 expression during immune- or targeted therapy in advanced melanoma. NEOPLASIA. 2018;20(2):218–25.
MLA
Krähenbühl, Lukas, Simone M Goldinger, Joanna Mangana, et al. “A Longitudinal Analysis of IDO and PDL1 Expression During Immune- or Targeted Therapy in Advanced Melanoma.” NEOPLASIA 20.2 (2018): 218–225. Print.
@article{8566836,
  abstract     = {A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma patients treated with IT and targeted therapy (TT). Intraindividual biopsies taken after a period of weeks to months demonstrate discordant results in 30% of the cases. Overlap of IDO and PDL1 increased after therapy. IT only marginally impacted PDL1 expression over time in contrast to TT. Standardized repeated assessments of multiple immune markers in repeated biopsies will generate detailed insights in melanoma's immune evolution and adaption during therapies and might be used to support treatment decisions.},
  author       = {Krähenbühl, Lukas and Goldinger, Simone M and Mangana, Joanna and Kerl, Katrin and Chevolet, Ines and Brochez, Lieve and Horak, Christine and Levesque, Mitch and Dummer, Reinhard and Cheng, Phil F},
  issn         = {1476-5586},
  journal      = {NEOPLASIA},
  keywords     = {CLINICAL-PRACTICE GUIDELINES,INDOLEAMINE 2,3-DIOXYGENASE,UNTREATED MELANOMA,CANCER,NIVOLUMAB,IPILIMUMAB,DIAGNOSIS,ANTIBODY,MARKER,PD-L1},
  language     = {eng},
  number       = {2},
  pages        = {218--225},
  title        = {A longitudinal analysis of IDO and PDL1 expression during immune- or targeted therapy in advanced melanoma},
  url          = {http://dx.doi.org/10.1016/j.neo.2017.12.002},
  volume       = {20},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: